OR WAIT 15 SECS
© 2020 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2020 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
The ACR says that ANA subserology testing in conditions such as rheumatoid arthritis is rarely justified. Many rheumatologists are not acting accordingly. Why not?
Two new strategies for breaking through the tangle of pathways to identify those most important to rheumatoid arthritis treatment converge on a shared goal: personalized medicine.
Acronym alert: European rheumatologists are proposing new subtypes of disease-modifying antirheumatic drugs, prompted by advances in methods of drug development.
Recent English-language guidelines agree that rheumatoid arthritis (RA) needs to prompt treatment. But the definition of "early RA," and the regimens, differ considerably.